- Home
- MMV vs CARA Comparison
MMV vs CARA Comparison
Compare MMV & CARA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MMV
- CARA
- Stock Information
- Founded
- MMV 2015
- CARA 2004
- Country
- MMV China
- CARA United States
- Employees
- MMV N/A
- CARA N/A
- Industry
- MMV Blank Checks
- CARA Biotechnology: Pharmaceutical Preparations
- Sector
- MMV Finance
- CARA Health Care
- Exchange
- MMV Nasdaq
- CARA Nasdaq
- Market Cap
- MMV 14.1M
- CARA 15.1M
- IPO Year
- MMV N/A
- CARA 2014
- Fundamental
- Price
- MMV $0.37
- CARA $0.31
- Analyst Decision
- MMV
- CARA Hold
- Analyst Count
- MMV 0
- CARA 3
- Target Price
- MMV N/A
- CARA $1.00
- AVG Volume (30 Days)
- MMV 847.4K
- CARA 909.3K
- Earning Date
- MMV 01-01-0001
- CARA 11-14-2024
- Dividend Yield
- MMV N/A
- CARA N/A
- EPS Growth
- MMV N/A
- CARA N/A
- EPS
- MMV N/A
- CARA N/A
- Revenue
- MMV $9,008,244.00
- CARA $8,686,000.00
- Revenue This Year
- MMV N/A
- CARA N/A
- Revenue Next Year
- MMV N/A
- CARA N/A
- P/E Ratio
- MMV N/A
- CARA N/A
- Revenue Growth
- MMV N/A
- CARA N/A
- 52 Week Low
- MMV $0.32
- CARA $0.24
- 52 Week High
- MMV $2.05
- CARA $1.31
- Technical
- Relative Strength Index (RSI)
- MMV 44.92
- CARA 53.07
- Support Level
- MMV $0.34
- CARA $0.28
- Resistance Level
- MMV $0.41
- CARA $0.32
- Average True Range (ATR)
- MMV 0.04
- CARA 0.03
- MACD
- MMV 0.00
- CARA -0.00
- Stochastic Oscillator
- MMV 38.54
- CARA 35.16
About MMV MultiMetaVerse Holdings Limited
MultiMetaVerse Holdings Ltd is an animation and entertainment company. It is devoted to establishing an open community for its global users comprised of animation viewers, game players, and content creators and to providing high-quality and immersive entertainment experiences by way of original content, user-generated content, and professional user-generated content.
About CARA Cara Therapeutics Inc.
Cara Therapeutics Inc is a development-stage biotechnology company involved in the development of novel therapeutics to treat human diseases associated with inflammation, pain, and pruritus. Cara's most advanced compound, CR845, aims to treat acute pain and pruritus. This patented compound has analgesic, anti-inflammatory, and antipruritic properties that can be used for multiple therapeutic applications. Additionally, Cara's objective is to use its proprietary drug-screening technology to develop a future pipeline of first-in-class molecules with analgesic and anti-inflammatory features.